Aspirin (NSC 27223)

Catalog No.S3017 Synonyms: Acetylsalicylic acid, ASA

For research use only.

Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.

Aspirin (NSC 27223) Chemical Structure

CAS No. 50-78-2

Selleck's Aspirin (NSC 27223) has been cited by 18 publications

Purity & Quality Control

Choose Selective COX Inhibitors

Other COX Products

Biological Activity

Description Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.
Targets
COX2 [1] COX1 [1]
In vitro

Aspirin inhibits the activation of NF-kappa B, thus prevents the degradation of the NF-kappa B inhibitor, I kappa B, and therefore NF-kappa B is retained in the cytosol. Aspirin also inhibits NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells. [1] Aspirin and salicylate are mediated in part by their specific inhibition of IKK-beta, thereby preventing activation by NF-kappaB of genes involved in the pathogenesis of the inflammatory response. [2] Aspirin is protective against neurotoxicity elicited by the excitatory amino acid glutamate in rat primary neuronal cultures and hippocampal slices. [3] Aspirin triggers transcellular biosynthesis of a previously unrecognized class of eicosanoidsduring coincubations of human umbilical vein endothelial cells (HUVEC) and neutrophils [polymorphonuclear leukocytes (PMN)]. Aspirin evokes a unique class of eicosanoids formed by acetylated PGHS-2 and 5-lipoxygenase interactions. [4] Aspirin treatment inhibits the phosphorylation of IRS-1 at Ser307 as well as the phosphorylation of JNK, c-Jun, and degradation of IkappaBalpha in 3T3-L1 and Hep G2 cells treated with tumor necrosis factor (TNF)-alpha. Aspirin treatment inhibits phosphorylation of Akt and the mammalian target of rapamycin (but not extracellular regulated kinase or PKCzeta) in response to TNF-alpha. Aspirin rescues insulin-induced glucose uptake in 3T3-L1 adipocytes pretreated with TNF-alpha. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
AGS M4XRN2Z2dmO2aX;uJIF{e2G7 NV\aNYlCOTVidH:gOlAhfW2xbD;MJIFnfGW{ MmLVNVIhcHK| MUfJcohq[mm2aX;uJI9nKEW|Y3jldolkcGmjIHPvcIkue3SrbYXsZZRm\CCLTD24JJBzd2S3Y4Tpc44hcW5iaIXtZY4hSUeVIHPlcIx{KGG2IEG1JJRwKDZyIIXtc4wwVCCjZoTldkAyOiCqcoOgZpkhTUyLU1G= M4DZVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUWzNVg{Lz5{MEG1N|E5OzxxYU6=
microglia cells Mk\4RY51cW6ndYLvbY5ndGGvbXH0c5J6KGG|c3H5 MkfaNVUhdWmwcx?= MXLBcpRqdmW3cn;pcoZt[W2vYYTvdpkh[WO2aY\peJkhcW5iTGDTMZN1cW23bHH0[YQhemG2IH3pZ5Jw\2yrYTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFCPQT3zeIlufWyjdHXkJHRZSjJicnXs[YF{\SCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMhdWWjc4Xy[YQhPzBibXnud{Bi\nSncjDQUWEh[2ijbHzlcodmNCCLQ{WwQVMvOTMQvF2= MnfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNUO4O|QoRjJ{MUWzPFc1RC:jPh?=
HCT116 NHjEZmdHfW6ldHnvckBie3OjeR?= M1HMe|EhdU1? NILJO5M3KGi{cx?= M4LEVmlvcGmkaYTpc44hd2ZiVF7GMYFteGijLXnu[JVk\WRiTl[tb4FxeGGEIHHjeIl3[XSrb36gbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG2IEGgcW0h[W[2ZYKgOkBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 M2XYPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUW0PFM1Lz5{MkG1OFg{PDxxYU6=
SKBR3 MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWjW[I51OzByIIXN MVK0PEBpenN? NYDINGtlT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW0uEUkOgZ4VtdHNiYYSgN|AxKHWPIHHmeIVzKDR6IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigQ>? NWLNdVN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVQ3OTdpPkKyOFk1PjF5PD;hQi=>
PANC1 M4H2cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mo\KN|AxKHWP M1XUNVQ5KGi{cx?= M3rjNWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBCVkNzIHPlcIx{KGG2IEOwNEB2VSCjZoTldkA1QCCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZk> NWfLb3dERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVQ3OTdpPkKyOFk1PjF5PD;hQi=>
PC3 Mk\zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M135[FMxOCC3TR?= MWK0PEBpenN? MVTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQR|Mh[2WubIOgZZQhOzByIIXNJIFnfGW{IES4JIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeR?= NYHOdZN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVQ3OTdpPkKyOFk1PjF5PD;hQi=>
MDA-MB-231 MVTGeY5kfGmxbjDhd5NigQ>? M4WyflExOCC3TR?= Mn7sN|AhdWmwcx?= NWXUfoZpUXK{ZY\ldpNq[mynIHnubIljcXSrb36gc4YhS0:[LUGgbY4hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHyZYNpcWSxbnnjJIFkcWRvaX7keYNm\CCSR1WyJIZwem2jdHnvckBifCBzMECgeW0hcW6ldXLheIVlKG[xcjCzNEBucW6|IH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgN|AhdWmwczDwc5N1KGG{YXPobYRwdmmlIHHjbYQh[2ijbHzlcodmKGK7IILh[IlwcW2vdX7vZZN{[Xl? M2LNVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkWxN|U6Lz5{M{[1NVM2QTxxYU6=
THP1 M3\aSGZ2dmO2aX;uJIF{e2G7 NXHvfYV5OTByIIXN M2PvWVMxKG2rboO= NXnsdpBYUXK{ZY\ldpNq[mynIHnubIljcXSrb36gc4YhS0:[LUGgbY4hcHWvYX6gWGhROSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIFz[WOqaXTvcolkKGGlaXStbY5lfWOnZDDUXGIzKG[xcn3heIlwdiCjdDCxNFAhfU1iaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3jveZQhdWWjc4Xy[YQhOzBibXnud{Bxd3O2IHHyZYNpcWSxbnnjJIFkcWRiY3jhcIxmdmenIHL5JJJi\GmxaX3teY5w[XO|YYm= Mn\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4NUGzOVkoRjJ|NkWxN|U6RC:jPh?=
HCT116 Moj5R5l1d3SxeHnjbZR6KGG|c3H5 MnKzOFghcHK| NIjNU2tEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCPVGSgZZN{[Xl? NX\t[XQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVA1ODFpPkK2O|UxPDBzPD;hQi=>
H9c2 MlPHR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? M4CzdVEhfU1? MVy4JIhzew>? MkLIR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDJUE03KGmwIIP1dIVzdmG2YX70JIF1KDFidV2gdJJmcW6ldXLheIVlKG[xcjC4JIhzeyCob3zsc5dm\CCkeTDINm8zKGGmZHn0bY9vKG[xcjCyJIhzeyCkeTDFUGlUSQ>? MoXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 NXfOPFI6S2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= MUGxJJVO MV64JIhzew>? NV;1NIlbS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IH3l[IlifGWmIHnu[oxidW2jdHnvckBqdiC{YYSgTFlkOiClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBVVkZvYXzwbIEhcW5ic4Xw[ZJv[XSjboSgZZQhOSC3TTDwdoVqdmO3YnH0[YQh\m:{IEigbJJ{KG[xbHzve4VlKGK7IFiyU|Ih[WSmaYTpc44h\m:{IEKgbJJ{KGmwIIDy[ZNmdmOnIH;mJIxmd263cnnu[UBjgSCH NV[1WHExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 M2jZ[2NiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl? NVLYR3hwOSC3TR?= MU[4JIhzew>? MXXDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC|dILld5MhcW5icnH0JGg6[zJiY3XscJMh[XO|ZYPz[YQh[XNiYX70bY95cWSjboSgZYN1cX[rdImgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDNSGEhdGW4ZXzzJIF1KDFidV2gdJJmcW6ldXLheIVlKG[xcjC4JIhzeyCob3zsc5dm\CCkeTDINm8zKGGmZHn0bY9vKG[xcjCyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{eR?= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 Mn\3R4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>? MnvFNUB2VQ>? Mn\rPEBpenN? M1vHZWNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCrbjDyZZQhUDmlMjDj[YxteyCjc4Pld5Nm\CCjczDhcpRqd3irZHHueEBi[3Srdnn0fUBjgSCvZXHzeZJqdmdiaX7jdoVie2ViaX6gV29FKGGldHn2bZR6KGG2IEGgeW0heHKnaX7jeYJifGWmIH\vdkA5KGi{czDmc4xtd3enZDDifUBJOk9{IHHk[Il1cW:wIH\vdkAzKGi{czDifUB{eGWldILvdIhwfG:vZYTyfS=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 NVzHZW4zS2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= M2\EdFEhfU1? NGLxZVg5KGi{cx?= M3HGbmNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCrbjDyZZQhUDmlMjDj[YxteyCjc4Pld5Nm\CCjczDhcpRqd3irZHHueEBi[3Srdnn0fUBjgSCvZXHzeZJqdmdiaX7jdoVie2ViaX6gZ4F1[Wyjc3WgZYN1cX[rdImgZZQhOSC3TTDwdoVqdmO3YnH0[YQh\m:{IEigbJJ{KG[xbHzve4VlKGK7IFiyU|Ih[WSmaYTpc44h\m:{IEKgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHK7 NIfhVWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W3OVQ4OSd-Mke1O|U1PzF:L3G+
H9c2 M4qwXGNiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl? M{PheFEhfU1? NFnFenU5KGi{cx?= MmHBR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDUUmYu[WyyaHGgbY4he3WyZYLuZZRidnRiYYSgNUB2VSCycnXpcoN2[mG2ZXSg[o9zKDhiaILzJIZwdGyxd3XkJIJ6KEh{T{KgZYRlcXSrb36g[o9zKDJiaILzJIJ6KEWOSWPB MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 NXniOm9wS2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= MYixJJVO NUWzcmRyQCCqcoO= NES3PIVE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NibXXkbYF1\WRiaX7mcIFudWG2aX;uJIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGlNNTGkZYThJIlvKHO3cHXycoF1[W62IHH0JFEhfU1icILlbY5kfWKjdHXkJIZweiB6IHjyd{Bnd2yub4fl[EBjgSCKMl:yJIFl\Gm2aX;uJIZweiB{IHjyd{BjgSCHTFnTRS=> MoDlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 NFPSSWNE[XKmaX;wdo91\WO2aY\lJIF{e2G7 MkS5NUB2VQ>? MYm4JIhzew>? NU\1WGNGS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO|IHnuJJJifCCKOXOyJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCPRFGgcIV3\Wy|IHH0JFEhfU1icILlbY5kfWKjdHXkJIZweiB6IHjyd{Bnd2yub4fl[EBjgSCKMl:yJIFl\Gm2aX;uJIZweiB{IHjyd{BqdiCycnXz[Y5k\SCxZjDs[Y9vfXKrbnWgZpkhe3CnY4Tyc5Bpd3SxbXX0dpk> NV63UphERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2 MY\DZZJlcW:ycn;0[YN1cX[nIHHzd4F6 NETNOYcyKHWP MkTkPEBpenN? MnfBR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KGmwIILheEBJQWN{IHPlcIx{KGG|c3Xzd4VlKGG|IHHueIlwgGmmYX70JIFkfGm4aYT5JIJ6KG2nYYP1dolv\yCrbnPy[YF{\SCrbjDTU2Qh[WO2aY\peJkh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK|IHnuJJBz\XOnbnPlJI9nKGynb371dolv\SCkeTDzdIVk MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O|E9N2F-
H9c2 MY\DZZJlcW:ycn;0[YN1cX[nIHHzd4F6 MX6xJJVO M4\jblghcHK| M4H1[mNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCvZXTpZZRm\CCrbn\sZY1u[XSrb36gbY4hemG2IFi5Z|Ih[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gTWwuPiCrbjDzeZBmem6jdHHueEBifCBzIIXNJJBz\WmwY4XiZZRm\CCob4KgPEBpenNiZn;scI94\WRiYomgTFJQOiCjZHTpeIlwdiCob4KgNkBpenNiaX6gdJJme2WwY3Wgc4YhdGWxboXybY5mKGK7IFXMTXNC MlPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
H9c2 NU[5dFNOS2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= NWXH[4ZZOSC3TR?= NFLyWnA5KGi{cx?= MmezR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDJUE0y[mW2YTDpckB{fXCncn7heIFvfCCjdDCxJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhQCCqcoOg[o9tdG:5ZXSgZpkhUDKRMjDh[IRqfGmxbjDmc5IhOiCqcoOgbY4heHKnc3XuZ4Uhd2ZibHXvcpVzcW6nIHL5JGVN M3X0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2 NV7Rb4tlS2G{ZHnvdJJwfGWldHn2[UBie3OjeR?= Mnr2NUB2VQ>? M{jRZ|ghcHK| MVnDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKGO7dH;0c5hq[2m2eTDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBifCBzIIXNJJBz\WmwY4XiZZRm\CCob4KgPEBpenNiZn;scI94\WRiYomgTFJQOiCjZHTpeIlwdiCob4KgNkBpenNiYomgUXRVKGG|c3H5 MlvNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O|EoRjJ5NUe1OFcyRC:jPh?=
RAW264.7 MUfBcpRqcW6obHHtcYF1d3K7IHHzd4F6 NYfqbWdxSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIHL5JI1m[XO3cnnu[{BvcXS{aYTlJIFk[3WvdXzheIlwdiCkeTDHdolme3NibXX0bI9lNCCLQ{WwQVQ{NjMQvF2= NGLy[4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW2NVU5Pid-Mki1OlE2QDZ:L3G+
stem cells MVrGeY5kfGmxbjDhd5NigQ>? MnzMNVAxKHWP NWX3fJQyPSCmYYnz M1uxW2lv\HWldHnvckBw\iCjZHnwc4dmdmW|aYOgbY4hcHWvYX6gZo9v\SCvYYLyc5cu\GW{aY\l[EBu\XOnbnPofY1idCC|dHXtJINmdGy|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGGmaYDvcoVkfGmwIIDyc4R2[3Srb36gZZQhOTByIIXNJI1m[XO3cnXkJI9vKGSjeTC1JIlvKHC{ZYPlcoNmKG:oIFnEXEBjgSCHTFnTRS=> NV71VZJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzPVg1PDNpPkK5N|k5PDR|PD;hQi=>
DAOY MnfTdWhVWyCjc4PhfS=> MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? MoS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh30 NEf2[HhyUFSVIHHzd4F6 MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 MmXDdWhVWyCjc4PhfS=> MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? M4LnZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
peritoneal cells NV\JTmxNTnWwY4Tpc44h[XO|YYm= NX2xcHFRPSCqcoO= Mmr2TY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDQS2UzKHC{b3T1Z5Rqd25iaX6gR|U4Skx4IH3veZNmKHCncnn0c45m[WxiY3XscJMhdWWjc4Xy[YQh[XRiNTDodpMhfGmvZTDpcpRmen[jbDDifUBGVEmVQTygTWM2OD12LkC4{txO NGrQ[JM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE4Oid-M{CwNFYyPzJ:L3G+
HCT8 MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NUDqPWQ6PzJiaILz MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEigZ4VtdHNiYX\0[ZIhPzJiaILzJIlvKHC{ZYPlcoNmKG:oIHPpco5idWGuZHXofYRmKGK7IF3UWEBie3OjeTygTWM2OD1zNT62{txO MnHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{e0PVQoRjNyMEO3OFk1RC:jPh?=
RPMI8226 NGDWcZFE\WyuIHP5Z4xmKGG|c3H5 M13jTFEvPyC3TR?= MoH4OFghcHK| MXPD[YxtKGO7Y3zlJIFzemW|dDDpckBpfW2jbjDSVG1KQDJ{NjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS|EheGijc3WgZZQhOS55IIXNJIlvKHC{ZYPlcoNmKG:oIHLvdpRmgm:vaXKgZYZ1\XJiNEigbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVxUl7hd4Uhe3SjaX7pcoch[mG|ZXSg[oxwfyCleYTvcYV1emmlIH3leIhw\CC{ZXzheIl3\SC2bzDic5J1\XqxbXni NEL6TZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW5NFI2QCd-M{C1PVAzPTh:L3G+
RPMI8226 Mm\kR4VtdCCleXPs[UBie3OjeR?= MUmxMlchfU1? M2P3[|Q5KGi{cx?= Mm\tR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gVnBOUTh{Mk[gZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IGOgdIhie2ViYYSgNU44KHWPIHnuJJBz\XOnbnPlJI9nKGKxcoTlfo9ucWJiYX\0[ZIhPDhiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUwWk6jc3Wgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dolkKG2ndHjv[EBz\WyjdHn2[UB1dyCkb4L0[ZpwdWmk NIjKNlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW5NFI2QCd-M{C1PVAzPTh:L3G+
RPMI8226 M{jnNWNmdGxiY4njcIUh[XO|YYm= MmHjNU44KHWP M4rlWlQ5KGi{cx?= NH;YSIxE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBTWE2LOEKyOkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2ViYYSgNU44KHWPIHnuJJBz\XOnbnPlJI9nKGKxcoTlfo9ucWJiYX\0[ZIhPDhiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUwWk6jc3Wgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dolkKG2ndHjv[EBz\WyjdHn2[UB1dyCkb4L0[ZpwdWmk NVqxdZhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C1PVAzPThpPkOwOVkxOjV6PD;hQi=>
HaCaT MUXBcpRqeHm{ZYTpZ{Bie3OjeR?= NHLQcIQyODBidV2= M1GxSlIhcHK| NUCxW5NuSW62aYD5doV1cWNiYXP0bZZqfHliaX6gbJVu[W5iSHHDZXQh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDUUmZidHCqYT3pcoR2[2WmIGDHSVIheHKxZIXjeIlwdiCjdDCxNFAhfU1icILlMYlv[3WkYYTl[EBnd3JiMjDodpMh[mWob4LlJHRPTmGucHjhJJN1cW23bHH0bY9vKG[xcjCyOEBpenNiYomgSWxKW0F? NF\xNo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MUO5N|EzPSd-M{GzPVMyOjV:L3G+
OVCAR5 MVnGeY5kfGmxbjDhd5NigQ>? NFz5Umo{ODBidV2geI8hOSCvTR?= MmKwO|IhcHK| NIrYWIFKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKE:YQ1HSOUBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IF\LPFY3NWmwZIXj[YQh[3m2b4TvfIlkcXS7IHL5JI1m[XO3cnnu[{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[XRiM{CwJJVOKHSxIEGgcW0hcW6ldXLheIVlKG[xcjC3NkBpenNiYomgV3JDKGG|c3H5 Mlm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlUwLz6FaFXNRmw9N2F-
CCRF-CEM Ml:ySpVv[3Srb36gZZN{[Xl? MmrsN{42KG2P M{KwVlQ5KGi{cx?= NX;tTmo1UW6qaXLpeIlwdiCxZjDORXBTXCCrbjDoeY1idiCFQ2LGMWNGVSClZXzsd{Bie3Onc4Pl[EBieyCyb4TlcpRq[XSrb36gc4YhVkGPUGSgbY5pcWKrdH;yJGZMQDZ4LXnu[JVk\WRiYYDvdJRwe2m|IHL5JI1m[XO3cnnu[{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[XRiMz61JI1OKHC{ZYKtbY5kfWKjdHXkJJdqfGhiSVO1NEBt\X[nbDDv[kBHUzh4NjDmc5IhPDhiaILzJIZwdGyxd3XkJIJ6KGOxbYDveY5lKGGmZHn0bY9vKGGwZDDmeZJ1cGW{ NFLye2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
Jurkat M4CwRmZ2dmO2aX;uJIF{e2G7 MnH2N{42KG2P MVO0PEBpenN? NVfvWpZqUW6qaXLpeIlwdiCxZjDORXBTXCCrbjDoeY1idiCMdYLrZZQh[2WubIOgZZN{\XO|ZXSgZZMheG:2ZX70bYF1cW:wIH;mJG5CVVCWIHnubIljcXSxcjDGT|g3Pi2rbnT1Z4VlKGGyb4D0c5NqeyCkeTDt[YF{fXKrbnegdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIF1KDNwNTDtUUBxemW{LXnuZ5Vj[XSnZDD3bZRpKEmFNUCgcIV3\Wxib3[gSms5PjZiZn;yJFQ5KGi{czDmc4xtd3enZDDifUBkd22yb4Xu[EBi\GSrdHnvckBidmRiZoXyeIhmeiCr MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
ML2 MYTGeY5kfGmxbjDhd5NigQ>? MljVN{42KG2P NEnWSnk1QCCqcoO= NFTnRYJKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKE2OMjDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv[3V? M1;0VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
NOMO NETqe5VHfW6ldHnvckBie3OjeR?= NIX3Rm8{NjVibV2= MVy0PEBpenN? NHjOemhKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKE6RTV:gZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIFxd3C2b4Ppd{BjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFMvPSCvTTDwdoVzNWmwY4XiZZRm\CC5aYToJGlEPTBibHX2[Ywhd2ZiRlu4OlYh\m:{IES4JIhzeyCob3zsc5dm\CCkeTDjc41xd3WwZDDh[IRqfGmxbjDhcoQh\nW{dHjldkBqdmN? NInScZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
NB4 Mn;ESpVv[3Srb36gZZN{[Xl? NV;2bXY2Oy53IH3N MlfPOFghcHK| M2HPUmlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hVkJ2IHPlcIx{KGG|c3Xzd4VlKGG|IIDveIVvfGmjdHnvckBw\iCQQV3QWEBqdmirYnn0c5IhTkt6Nk[tbY5lfWOnZDDhdI9xfG:|aYOgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCzMlUhdU1icILldk1qdmO3YnH0[YQhf2m2aDDJR|UxKGyndnXsJI9nKE[NOE[2JIZweiB2ODDodpMh\m:ubH;3[YQh[nliY3;tdI92dmRiYXTkbZRqd25iYX7kJIZ2enSqZYKgbY5kfQ>? MmWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlUwLz6FaFXNRmw9N2F-
NAMALWA MlvnSpVv[3Srb36gZZN{[Xl? Ml\sN{42KG2P MoDzOFghcHK| NIj6dWNKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKE6DTVHMW2Eh[2WubIOgZZN{\XO|ZXSgZZMheG:2ZX70bYF1cW:wIH;mJG5CVVCWIHnubIljcXSxcjDGT|g3Pi2rbnT1Z4VlKGGyb4D0c5NqeyCkeTDt[YF{fXKrbnegdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIF1KDNwNTDtUUBxemW{LXnuZ5Vj[XSnZDD3bZRpKEmFNUCgcIV3\Wxib3[gSms5PjZiZn;yJFQ5KGi{czDmc4xtd3enZDDifUBkd22yb4Xu[EBi\GSrdHnvckBidmRiZoXyeIhmeg>? NHm5Uo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
Daudi NWrVV2NGTnWwY4Tpc44h[XO|YYm= M2e0fVMvPSCvTR?= M2XhclQ5KGi{cx?= NGfM[m5KdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKESjdXTpJINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiRlu4OlYucW6mdXPl[EBieG:ydH;zbZMh[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA{NjVibV2gdJJmei2rbnP1ZoF1\WRid3n0bEBKSzVyIHzleoVtKG:oIF\LPFY3KG[xcjC0PEBpenNiZn;scI94\WRiYomgZ49ueG:3bnSgZYRlcXSrb36gZY5lKG[3coTo[ZIhcW5? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
Raji M3PqbmZ2dmO2aX;uJIF{e2G7 MUmzMlUhdU1? M1z2RVQ5KGi{cx?= NF\nZWRKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKFKjanmgZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIFxd3C2b4Ppd{BjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFMvPSCvTTDwdoVzNWmwY4XiZZRm\CC5aYToJGlEPTBibHX2[Ywhd2ZiRlu4OlYh\m:{IES4JIhzeyCob3zsc5dm\CCkeTDjc41xd3WwZDDh[IRqfGmxbjDhcoQh\nW{dHjldkBqdmN? MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
ARH77 MmS5SpVv[3Srb36gZZN{[Xl? MmfUN{42KG2P NEXJdZc1QCCqcoO= NFz5dVFKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKEGUSEe3JINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiRlu4OlYucW6mdXPl[EBieG:ydH;zbZMh[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA{NjVibV2gdJJmei2rbnP1ZoF1\WRid3n0bEBKSzVyIHzleoVtKG:oIF\LPFY3KG[xcjC0PEBpenNiZn;scI94\WRiYomgZ49ueG:3bnSgZYRlcXSrb36gZY5lKG[3coTo[ZIhcW5? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
RPMI8226 NWXOVYpXTnWwY4Tpc44h[XO|YYm= MVGzMlUhdU1? MoPLOFghcHK| MUjJcohq[mm2aX;uJI9nKE6DUGLUJIlvKGi3bXHuJHJRVUl6MkK2JINmdGy|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiRlu4OlYucW6mdXPl[EBieG:ydH;zbZMh[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA{NjVibV2gdJJmei2rbnP1ZoF1\WRid3n0bEBKSzVyIHzleoVtKG:oIF\LPFY3KG[xcjC0PEBpenNiZn;scI94\WRiYomgZ49ueG:3bnSgZYRlcXSrb36gZY5lKG[3coTo[ZI> M3zOPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
U266 NV\4O3ZNTnWwY4Tpc44h[XO|YYm= MUCzMlUhdU1? Ml3BOFghcHK| MmnLTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBWOjZ4IHPlcIx{KGG|c3Xzd4VlKGG|IIDveIVvfGmjdHnvckBw\iCQQV3QWEBqdmirYnn0c5IhTkt6Nk[tbY5lfWOnZDDhdI9xfG:|aYOgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCzMlUhdU1icILldk1qdmO3YnH0[YQhf2m2aDDJR|UxKGyndnXsJI9nKE[NOE[2JIZweiB2ODDodpMh\m:ubH;3[YQh[nliY3;tdI92dmRiYXTkbZRqd25iYX7kJIZ2enSqZYKgbY5k NFHiT|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
NAMALWA MWTGeY5kfGmxbjDhd5NigQ>? M{f1PVM2KG2pL3vn NULSNYI2PDViZHH5dy=> NUCySYdOWG:2ZX70bYF1cW:wIH;mJG5CVVCWIHnubIljcXSxcjCxNEBu\y:tZzygbZAh[mmmIF\LPFY3NWmwZIXj[YQh[W62aYT1cY9zKGGldHn2bZR6KGmwIHj1cYFvKE6DTVHMW2Eh[2WubIOgfIVvd2e{YX\0[YQhcW5iU1PJSEBud3W|ZTDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCvb4Xz[UB{fXK4aY\hcEBifCB|NTDt[{9s\yxiaYCgZollKHWyIITvJFQ2KGSjeYO= NX7NWZZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
Assay
Methods Test Index PMID
Western blot SHH / SMO / GLI1 / Bcl-2 / Foxm1 ; ; p-AMPKα / AMPKα / p-ACC / ACC ; p-AKT / AKT / p-ERK / ERK ; MCL-1 28446712 23741443 26918349
Growth inhibition assay Cell viability ; Cell proliferation 30221683 28446712

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 36 mg/mL
(199.82 mM)
Water Insoluble
Ethanol ''36 mg/mL

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
4% DMSO+PBS
For best results, use promptly after mixing.

10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 180.16
Formula

C9H8O4

CAS No. 50-78-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(=O)OC1=CC=CC=C1C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04563546 Not yet recruiting Other: Quality Improvement Acute Coronary Syndrome Duke University January 1 2023 Not Applicable
NCT05031455 Not yet recruiting Biological: Dupilumab|Drug: Placebo Aspirin-exacerbated Respiratory Disease Scripps Clinic|University of California San Diego|Regeneron Pharmaceuticals January 1 2022 Phase 2
NCT05166096 Recruiting Drug: Rho-11|Drug: aspirin 325mg Healthy Rhoshan Pharmaceuticals Inc December 3 2021 Phase 1
NCT04308551 Not yet recruiting Drug: Indobufen|Drug: Aspirin Stable Coronary Heart Disease Henan Institute of Cardiovascular Epidemiology December 30 2021 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Aspirin (NSC 27223) | Aspirin (NSC 27223) supplier | purchase Aspirin (NSC 27223) | Aspirin (NSC 27223) cost | Aspirin (NSC 27223) manufacturer | order Aspirin (NSC 27223) | Aspirin (NSC 27223) distributor